IDEXX Laboratories, Inc. (IDXX)
- Previous Close
489.98 - Open
490.32 - Bid 491.73 x 100
- Ask 494.06 x 100
- Day's Range
487.30 - 493.77 - 52 Week Range
356.14 - 548.88 - Volume
281,183 - Avg. Volume
876,762 - Market Cap (intraday)
39.622B - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
45.49 - EPS (TTM)
10.83 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
496.54
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
www.idexx.com11,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IDXX
View More
![IDEXX Laboratories [NasdaqGS:IDXX] Raises 2025 Guidance and Reports Q1 Growth in Revenue and EPS](https://s.yimg.com/uu/api/res/1.2/_BiWuSn93zDqqyw3e1LFvw--~B/Zmk9c3RyaW07aD02Mzt3PTg0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09.cf.webp)
Performance Overview: IDXX
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IDXX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IDXX
View MoreValuation Measures
Market Cap
39.41B
Enterprise Value
40.30B
Trailing P/E
45.28
Forward P/E
40.65
PEG Ratio (5yr expected)
4.05
Price/Sales (ttm)
10.31
Price/Book (mrq)
27.21
Enterprise Value/Revenue
10.25
Enterprise Value/EBITDA
31.25
Financial Highlights
Profitability and Income Statement
Profit Margin
22.76%
Return on Assets (ttm)
22.98%
Return on Equity (ttm)
59.33%
Revenue (ttm)
3.93B
Net Income Avi to Common (ttm)
894.96M
Diluted EPS (ttm)
10.83
Balance Sheet and Cash Flow
Total Cash (mrq)
163.97M
Total Debt/Equity (mrq)
73.16%
Levered Free Cash Flow (ttm)
761.15M
Research Analysis: IDXX
View MoreResearch Reports: IDXX
View MoreRaising target price to $497.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $497.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetIdexx Earnings: Solid First-Quarter Performance Is Tempered by Potential for Recession
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
RatingPrice TargetRaising target price to $459.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $459.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetIdexx's Economic Moat Remains Solid, but Softer Consumer Confidence Could Weigh on Near Term
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
RatingPrice Target